When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression

Abstract

AbstractNext-generation sequencing has identified a number of mutations that are commonly found in patients with myeloid neoplasms that have clinical consequences. However, the mutations are complex and not always readily available. In this issue's Point Counterpoint, the authors argue whether they should be used to drive therapeutic decisions. Please share how these tests impact your practice using Remarq, an online collaboration tool for readers to make public comments.